Tarcocimab consistently demonstrated extended durability in multiple retinal vascular diseases across its pivotal studies 28 • Durability remains a key unmet need in retinal vascular diseases • Tarcocimab and the ABCD Platform demonstrated extended durability compared to today’s approved therapies across multiple indications • Favorable safety profile also demonstrated with 2,500+ patient years of experience and >13,000 injections ~60% on 5 - month dosing in wet AMD 100% on 6 - month dosing in DR 100% doubled dosing interval to Q8W in RVO 50% on 6 - month dosing in DME *Q12W after 1 year of effective therapy. ** Based on dosing interval at primary endpoint at year 1 in pivotal studies YOSEMITE and RHINE 1. Study did not meet primary endpoint believed to be due to the undertreatment of a minority of patients. 2. Studies did not meet primary endpoints due to an unforeseen increase in cataracts in tarcocimab - treated patients; Kodiak’s enhanced formulation may mitigate this liability.